az-3102
Niemann-Pick Type C Disease
Azafaros B.V.Phase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Niemann-Pick Type C Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Miglustat Actelion | Phase 4 | BBB |
Nizubaglustat Azafaros B.V. | Phase 3 | B |
N-Acetyl-L-Leucine IntraBio Inc | Phase 3 | B |
2-HYDROXYPROPYL BETA-CYCLODEXTRIN (DS 4.2) Vtesse, LLC, a Mallinckrodt Pharmaceuticals Company | Phase 2/3 | B |
Arimoclomol ZevraDenmark | Phase 2/3 | CCC |
View all 11 →
Same molecule, other indications
az-3102 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →